Anokion Announces $35 Million Equity Investment from Pfizer
Funding Supports Advancement of KAN-101 for Celiac Disease into Phase 2 Clinical Development
25-Oct-2022 -
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative. In conjunction with the investment, Michael ...
autoimmune diseases
celiac disease
gluten
+2